Therapeutic Studies of Primary CNS Malignancies-NABTT

描述（由申请人提供）：克利夫兰临床癌症中心脑肿瘤研究所（BTI）的一个主要目标是通过基础科学来推进脑肿瘤发展和生长机制的知识，并通过与工业和临床研究的工程合作来开发新的治疗方案。我们相信，NABTT联盟中持续的、长期的成员资格将是我们实现这一目标的主要手段。BTI每年进行600多例脑肿瘤手术，其中约150例是恶性神经胶质肿瘤。通过BTI的转化治疗中心，我们对新的、有前途的脑肿瘤药物进行临床前测试，确定它们的疗效和最佳的递送方式。其他的转化实验室工作包括脑肿瘤的过继免疫治疗和免疫系统调节，对流增强潜在疗法的传递，血清肿瘤标志物的检测，脑图像后处理或多模态集成以及用于评估治疗效果的纵向自分割和融合。我们打算在这些领域为NABTT联盟贡献有前途的新代理商和我们的专业知识。

DESCRIPTION (provided by applicant): A major thrust of The Brain Tumor Institute (BTI) of the Cleveland Clinic Cancer Center is to advance knowledge of the mechanisms of brain tumor development and growth, through basic science, and to develop new treatment options, by way of engineering collaboration with industry and clinical research. We believe that an ongoing, long-term membership in the NABTT consortium will be our principal means of achieving this goal. The BTI performs more than 600 brain tumor operations per year, of which approximately 150 are on malignant glial neoplasms. Through BTI's Center for Translational Therapeutics, we perform preclinical testing of new, promising brain tumor agents, determining their efficacy and optimum mode of delivery. Additional translational laboratory efforts include adoptive immunotherapy and immune system regulation for brain tumors, convection enhanced delivery of potential therapies, detection of serum tumor markers, and brain image post-processing or multimodality integration and longitudinal autosegmentation and fusion for assessment of treatment efficacy. It is our intention to contribute promising new agents and our expertise in these areas to the NABTT consortium. Since being accepted as a provisional member in NABTT 2 years ago, we have demonstrated our commitment to this organization by participating in or leading NABTT committees, protocol leadership, and having the highest second-year accrual of any active NABTT site, with a third-year projected accrual of about 28 patients. We believe that our yearly contribution of patients to the NABTT consortium will be in the range of 25 to 30 per year. Additional contributions to the Consortium will include 1) new agents with preclinical evidence of efficacy and optimal route of administration, 2) expertise in immunological strategies for brain tumor treatment, 3) new methods of integrating brain imaging and tracking changes over time, 4) expertise in advanced-agent delivery strategies such as convection enhanced delivery, 5) extensive expertise and state-of-art resources in radiotherapy, radiosurgery, surgical navigation, and neuro-imaging, 6) a broad, grant and endowment-supported basic science effort with capability to interface with other NABTT laboratories, 7) a large tumor bank with IRB-approved clinical/pathology/molecular/imaging database correlations, and 8) our expertise in generating and completing Phase I and II clinical trials.